CTOs on the Move

FemTec Health

www.femtechealth.com

 
Founded in May 2020 by Dr. Kimon Angelides and publicly launched in October 2021, FemTec Health is the leading Health and Beauty Sciences Company focused on women`s health. Angelides has brought together a female-led team with decades of experience across healthcare, wellness, and consumer products in public and private companies. FemTec Health`s mission is to revolutionize women`s healthcare by using state-of-the-art genomics, predictive intelligence, and digital technologies to create an experience that is unified, coordinated, and provides personalized services and products that are meaningful and effective for women. With offices in Houston, New York, San Diego, London, Barcelona, Athens & ...
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Semper Laser

Semper Laser is a laser hair removal company that specializes in providing affordable and advanced laser hair removal treatments for both men and women.

OptiScan Biomedical Corp

OptiScan Biomedical Corp is a Hayward, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Sequoia Project

The Sequoia Project is a non-profit 501c3 chartered to advance implementation of secure, interoperable nationwide health information exchange. The Sequoia Project supports health IT interoperability initiatives, most notably: the eHealth Exchange, a rapidly growing community of exchange partners who share information under a common trust framework and a common set of rules; and Carequality, a public-private collaborative effort to build consensus among existing data sharing networks regarding technical specifications and best practices, much like the telecommunications industry did for linking cell phone networks. The Sequoia Project leads in cross-industry collaboration to develop implementation strategies that enable secure, interoperable nationwide exchange of health information.

NovoLogix(SM)

NovoLogix is a cutting-edge Medical Pharmacy Benefit Management company.

OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.